Association of CYP3A5^*3, CYP3A4^*18 & CYP2B6^*6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients.

ABSTRACT:

Background & objectives

Imatinib mesylate (IM) is a reliable first line treatment for chronic myeloid leukaemia (CML). Nevertheless, despite promising results, a considerable proportion of patients develop resistance to the drug. Cytochrome P450 (CYP) enzymes play a crucial role in IM metabolism. Thus, point mutations in CYP genes may modify IM enzyme activity resulting in insufficient treatment response. This investigation was aimed to identify the functional impact of CYP3A5*3, CYP3A4*18 and CYP2B6*6 polymorphisms on the IM response in patients with CML in Azerbaijan.

Methods

Genotyping of CYP3A5*3, CYP3A4*18 and CYP2B6*6 was performed in 153 patients (102 IM non-responders and 51 IM responders) with CML by the PCR-restriction fragment length polymorphism (RFLP) assays. Th

SUBMITTER: Asadov C 

PROVIDER: S-EPMC10645035 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature